Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib second-line monotherapy in elderly EGFR/ALK/ROS1-negative lung adenocarcinoma patients refusing chemotherapy
ChiCTR1800017679Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in Non-small cell lung cancer adenocarcinoma (NSCLC) and non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Progression-free survival. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800017679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017679.